Health care resources utilization and costs associated with different clinical stages of chronic hepatitis B in Egypt
Introduction Chronic hepatitis B (CHB) is associated with many serious clinical and social consequences. Despite Egypt being classified as a country of low endemicity, the infection is associated with a 15–25% risk of premature death from liver cancer or end-stage liver disease. The national committ...
Gespeichert in:
Veröffentlicht in: | Egyptian Liver Journal 2021-12, Vol.11 (1), p.91-7, Article 91 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 7 |
---|---|
container_issue | 1 |
container_start_page | 91 |
container_title | Egyptian Liver Journal |
container_volume | 11 |
creator | Abd El-Halim, Jackleen Azer Gewaifel, Gihan Ismael Darwish, Eman Ahmed Fawzy Ramadan, Ahmed Maher ElSisi, Gihan Hamdy |
description | Introduction
Chronic hepatitis B (CHB) is associated with many serious clinical and social consequences. Despite Egypt being classified as a country of low endemicity, the infection is associated with a 15–25% risk of premature death from liver cancer or end-stage liver disease. The national committee of treatment and control of viral hepatitis has already offered a high-quality service for the diagnosis and treatment of CHB on a free basis. The current study aims to estimate the health care resources utilization and the annual direct medical cost associated with different clinical stages of CHB-related disease in Egypt.
Methodology
The data was retrieved through record review for three months in the General Administration of Hepatitis Viruses Control, Egypt. Then, the data was extrapolated to the population level by multiplying the prevalence in Egypt with a focus on the productive age groups (25–59 years).
Results
The cost and utilization of different health care resources increase with disease progression. The total annual direct medical costs due to CHB in Egypt is 21.3 L.E. Billion (4.7 Int$ billion/year) for the management of estimated 1,420,700 CHB patients. The direct medical costs among the productive age group (25–59 years) constitute more than half of the total cost (57%). The highest disease burden is encountered among (25–29 years) age group; 2.695 L.E. billion (0.59 Int$ billion/year). Despite liver transplantation phase being associated with the highest annual cost/patient, the number of patients in this stage is the lowest. Then, it only constitutes 0.04% of the disease direct medical cost in the country. The chronic hepatitis clinical stage constitutes 57.26% of the disease direct medical cost in Egypt’s working age group.
Conclusion
Strengthening the preventive and control measures is mandatory to alleviate the disease’s direct medical costs. Close monitoring of the chronic hepatitis stage is mandatory to prevent disease progression. Enhancement of vaccination efforts will lower the disease prevalence and its cost. The universal health insurance system which is gradually implemented in Egypt nowadays will be a cornerstone in relieving the economic stresses by allowing more access to high-quality health care services. |
doi_str_mv | 10.1186/s43066-021-00162-z |
format | Article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_proquest_journals_2812339394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A687542228</galeid><doaj_id>oai_doaj_org_article_831825314b3f4fde94d19de769cbc551</doaj_id><sourcerecordid>A687542228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-ad9f84316d4c8be5c6acc0b3511a8ef0d25d8bb9069748da1d88413c106b434a3</originalsourceid><addsrcrecordid>eNp9kktr3DAUhU1ooSHNH-hKkLVTvSzLyzSkTSDQTbsW11eSR4PHmkoaQubXV41LHlAqLSQO5ztcidM0nxi9ZEyrz1kKqlRLOWspZYq3x5PmlNOBtopz9e7V_UNznvOW1qVZT0V_2hxuHcxlQxCSI8nleEjoMjmUMIcjlBAXAoslGHPJBHKOGKA4Sx5ChWzw3iW3FIJzWALCTHKBqfLRE9ykWDWycfuaU0ImX0hYyM30uC8fm_ce5uzO_55nzc-vNz-ub9v779_urq_uW5SyLy3YwWspmLIS9eg6VIBIR9ExBtp5anln9TgOVA291BaY1VoygYyqUQoJ4qy5W3NthK3Zp7CD9GgiBPMkxDQZSCXg7IwWTPNOMDkKL711g7RssK5XA47YdaxmXaxZ-xR_HVwuZls_a6njG64ZF2IQg3xxTVBDw-JjSYC7kNFcKd13knOuq-vyH666rdsFjIvzoepvAL4CmGLOyfnnxzBq_pTArCUwtQTmqQTmWCGxQrmal8mll4n_Q_0G7nK0YA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2812339394</pqid></control><display><type>article</type><title>Health care resources utilization and costs associated with different clinical stages of chronic hepatitis B in Egypt</title><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><creator>Abd El-Halim, Jackleen Azer ; Gewaifel, Gihan Ismael ; Darwish, Eman Ahmed Fawzy ; Ramadan, Ahmed Maher ; ElSisi, Gihan Hamdy</creator><creatorcontrib>Abd El-Halim, Jackleen Azer ; Gewaifel, Gihan Ismael ; Darwish, Eman Ahmed Fawzy ; Ramadan, Ahmed Maher ; ElSisi, Gihan Hamdy</creatorcontrib><description>Introduction
Chronic hepatitis B (CHB) is associated with many serious clinical and social consequences. Despite Egypt being classified as a country of low endemicity, the infection is associated with a 15–25% risk of premature death from liver cancer or end-stage liver disease. The national committee of treatment and control of viral hepatitis has already offered a high-quality service for the diagnosis and treatment of CHB on a free basis. The current study aims to estimate the health care resources utilization and the annual direct medical cost associated with different clinical stages of CHB-related disease in Egypt.
Methodology
The data was retrieved through record review for three months in the General Administration of Hepatitis Viruses Control, Egypt. Then, the data was extrapolated to the population level by multiplying the prevalence in Egypt with a focus on the productive age groups (25–59 years).
Results
The cost and utilization of different health care resources increase with disease progression. The total annual direct medical costs due to CHB in Egypt is 21.3 L.E. Billion (4.7 Int$ billion/year) for the management of estimated 1,420,700 CHB patients. The direct medical costs among the productive age group (25–59 years) constitute more than half of the total cost (57%). The highest disease burden is encountered among (25–29 years) age group; 2.695 L.E. billion (0.59 Int$ billion/year). Despite liver transplantation phase being associated with the highest annual cost/patient, the number of patients in this stage is the lowest. Then, it only constitutes 0.04% of the disease direct medical cost in the country. The chronic hepatitis clinical stage constitutes 57.26% of the disease direct medical cost in Egypt’s working age group.
Conclusion
Strengthening the preventive and control measures is mandatory to alleviate the disease’s direct medical costs. Close monitoring of the chronic hepatitis stage is mandatory to prevent disease progression. Enhancement of vaccination efforts will lower the disease prevalence and its cost. The universal health insurance system which is gradually implemented in Egypt nowadays will be a cornerstone in relieving the economic stresses by allowing more access to high-quality health care services.</description><identifier>ISSN: 2090-6226</identifier><identifier>ISSN: 2090-6218</identifier><identifier>EISSN: 2090-6226</identifier><identifier>DOI: 10.1186/s43066-021-00162-z</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Age groups ; Broadway theater ; Chronic hepatitis B ; Control ; Development and progression ; Direct medical cost ; Disease ; Economic aspects ; Egypt ; Health care expenditures ; Health care industry ; Health care resources ; Hepatitis B ; Hepatology ; Hospitalization ; Infection ; Infections ; Laboratories ; Liver ; Liver cancer ; Liver cirrhosis ; Medical care ; Medical care, Cost of ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Morbidity ; Mortality ; National health insurance ; Original Research Article ; Patients ; Prevalence ; Questionnaires ; Transplantation of organs, tissues, etc ; Utilization</subject><ispartof>Egyptian Liver Journal, 2021-12, Vol.11 (1), p.91-7, Article 91</ispartof><rights>The Author(s) 2021</rights><rights>COPYRIGHT 2021 Springer</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c447t-ad9f84316d4c8be5c6acc0b3511a8ef0d25d8bb9069748da1d88413c106b434a3</cites><orcidid>0000-0002-1282-8521</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Abd El-Halim, Jackleen Azer</creatorcontrib><creatorcontrib>Gewaifel, Gihan Ismael</creatorcontrib><creatorcontrib>Darwish, Eman Ahmed Fawzy</creatorcontrib><creatorcontrib>Ramadan, Ahmed Maher</creatorcontrib><creatorcontrib>ElSisi, Gihan Hamdy</creatorcontrib><title>Health care resources utilization and costs associated with different clinical stages of chronic hepatitis B in Egypt</title><title>Egyptian Liver Journal</title><addtitle>Egypt Liver Journal</addtitle><description>Introduction
Chronic hepatitis B (CHB) is associated with many serious clinical and social consequences. Despite Egypt being classified as a country of low endemicity, the infection is associated with a 15–25% risk of premature death from liver cancer or end-stage liver disease. The national committee of treatment and control of viral hepatitis has already offered a high-quality service for the diagnosis and treatment of CHB on a free basis. The current study aims to estimate the health care resources utilization and the annual direct medical cost associated with different clinical stages of CHB-related disease in Egypt.
Methodology
The data was retrieved through record review for three months in the General Administration of Hepatitis Viruses Control, Egypt. Then, the data was extrapolated to the population level by multiplying the prevalence in Egypt with a focus on the productive age groups (25–59 years).
Results
The cost and utilization of different health care resources increase with disease progression. The total annual direct medical costs due to CHB in Egypt is 21.3 L.E. Billion (4.7 Int$ billion/year) for the management of estimated 1,420,700 CHB patients. The direct medical costs among the productive age group (25–59 years) constitute more than half of the total cost (57%). The highest disease burden is encountered among (25–29 years) age group; 2.695 L.E. billion (0.59 Int$ billion/year). Despite liver transplantation phase being associated with the highest annual cost/patient, the number of patients in this stage is the lowest. Then, it only constitutes 0.04% of the disease direct medical cost in the country. The chronic hepatitis clinical stage constitutes 57.26% of the disease direct medical cost in Egypt’s working age group.
Conclusion
Strengthening the preventive and control measures is mandatory to alleviate the disease’s direct medical costs. Close monitoring of the chronic hepatitis stage is mandatory to prevent disease progression. Enhancement of vaccination efforts will lower the disease prevalence and its cost. The universal health insurance system which is gradually implemented in Egypt nowadays will be a cornerstone in relieving the economic stresses by allowing more access to high-quality health care services.</description><subject>Age groups</subject><subject>Broadway theater</subject><subject>Chronic hepatitis B</subject><subject>Control</subject><subject>Development and progression</subject><subject>Direct medical cost</subject><subject>Disease</subject><subject>Economic aspects</subject><subject>Egypt</subject><subject>Health care expenditures</subject><subject>Health care industry</subject><subject>Health care resources</subject><subject>Hepatitis B</subject><subject>Hepatology</subject><subject>Hospitalization</subject><subject>Infection</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Medical care</subject><subject>Medical care, Cost of</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>National health insurance</subject><subject>Original Research Article</subject><subject>Patients</subject><subject>Prevalence</subject><subject>Questionnaires</subject><subject>Transplantation of organs, tissues, etc</subject><subject>Utilization</subject><issn>2090-6226</issn><issn>2090-6218</issn><issn>2090-6226</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNp9kktr3DAUhU1ooSHNH-hKkLVTvSzLyzSkTSDQTbsW11eSR4PHmkoaQubXV41LHlAqLSQO5ztcidM0nxi9ZEyrz1kKqlRLOWspZYq3x5PmlNOBtopz9e7V_UNznvOW1qVZT0V_2hxuHcxlQxCSI8nleEjoMjmUMIcjlBAXAoslGHPJBHKOGKA4Sx5ChWzw3iW3FIJzWALCTHKBqfLRE9ykWDWycfuaU0ImX0hYyM30uC8fm_ce5uzO_55nzc-vNz-ub9v779_urq_uW5SyLy3YwWspmLIS9eg6VIBIR9ExBtp5anln9TgOVA291BaY1VoygYyqUQoJ4qy5W3NthK3Zp7CD9GgiBPMkxDQZSCXg7IwWTPNOMDkKL711g7RssK5XA47YdaxmXaxZ-xR_HVwuZls_a6njG64ZF2IQg3xxTVBDw-JjSYC7kNFcKd13knOuq-vyH666rdsFjIvzoepvAL4CmGLOyfnnxzBq_pTArCUwtQTmqQTmWCGxQrmal8mll4n_Q_0G7nK0YA</recordid><startdate>20211220</startdate><enddate>20211220</enddate><creator>Abd El-Halim, Jackleen Azer</creator><creator>Gewaifel, Gihan Ismael</creator><creator>Darwish, Eman Ahmed Fawzy</creator><creator>Ramadan, Ahmed Maher</creator><creator>ElSisi, Gihan Hamdy</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><general>SpringerOpen</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1282-8521</orcidid></search><sort><creationdate>20211220</creationdate><title>Health care resources utilization and costs associated with different clinical stages of chronic hepatitis B in Egypt</title><author>Abd El-Halim, Jackleen Azer ; Gewaifel, Gihan Ismael ; Darwish, Eman Ahmed Fawzy ; Ramadan, Ahmed Maher ; ElSisi, Gihan Hamdy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-ad9f84316d4c8be5c6acc0b3511a8ef0d25d8bb9069748da1d88413c106b434a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age groups</topic><topic>Broadway theater</topic><topic>Chronic hepatitis B</topic><topic>Control</topic><topic>Development and progression</topic><topic>Direct medical cost</topic><topic>Disease</topic><topic>Economic aspects</topic><topic>Egypt</topic><topic>Health care expenditures</topic><topic>Health care industry</topic><topic>Health care resources</topic><topic>Hepatitis B</topic><topic>Hepatology</topic><topic>Hospitalization</topic><topic>Infection</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Medical care</topic><topic>Medical care, Cost of</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>National health insurance</topic><topic>Original Research Article</topic><topic>Patients</topic><topic>Prevalence</topic><topic>Questionnaires</topic><topic>Transplantation of organs, tissues, etc</topic><topic>Utilization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abd El-Halim, Jackleen Azer</creatorcontrib><creatorcontrib>Gewaifel, Gihan Ismael</creatorcontrib><creatorcontrib>Darwish, Eman Ahmed Fawzy</creatorcontrib><creatorcontrib>Ramadan, Ahmed Maher</creatorcontrib><creatorcontrib>ElSisi, Gihan Hamdy</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Egyptian Liver Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abd El-Halim, Jackleen Azer</au><au>Gewaifel, Gihan Ismael</au><au>Darwish, Eman Ahmed Fawzy</au><au>Ramadan, Ahmed Maher</au><au>ElSisi, Gihan Hamdy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Health care resources utilization and costs associated with different clinical stages of chronic hepatitis B in Egypt</atitle><jtitle>Egyptian Liver Journal</jtitle><stitle>Egypt Liver Journal</stitle><date>2021-12-20</date><risdate>2021</risdate><volume>11</volume><issue>1</issue><spage>91</spage><epage>7</epage><pages>91-7</pages><artnum>91</artnum><issn>2090-6226</issn><issn>2090-6218</issn><eissn>2090-6226</eissn><abstract>Introduction
Chronic hepatitis B (CHB) is associated with many serious clinical and social consequences. Despite Egypt being classified as a country of low endemicity, the infection is associated with a 15–25% risk of premature death from liver cancer or end-stage liver disease. The national committee of treatment and control of viral hepatitis has already offered a high-quality service for the diagnosis and treatment of CHB on a free basis. The current study aims to estimate the health care resources utilization and the annual direct medical cost associated with different clinical stages of CHB-related disease in Egypt.
Methodology
The data was retrieved through record review for three months in the General Administration of Hepatitis Viruses Control, Egypt. Then, the data was extrapolated to the population level by multiplying the prevalence in Egypt with a focus on the productive age groups (25–59 years).
Results
The cost and utilization of different health care resources increase with disease progression. The total annual direct medical costs due to CHB in Egypt is 21.3 L.E. Billion (4.7 Int$ billion/year) for the management of estimated 1,420,700 CHB patients. The direct medical costs among the productive age group (25–59 years) constitute more than half of the total cost (57%). The highest disease burden is encountered among (25–29 years) age group; 2.695 L.E. billion (0.59 Int$ billion/year). Despite liver transplantation phase being associated with the highest annual cost/patient, the number of patients in this stage is the lowest. Then, it only constitutes 0.04% of the disease direct medical cost in the country. The chronic hepatitis clinical stage constitutes 57.26% of the disease direct medical cost in Egypt’s working age group.
Conclusion
Strengthening the preventive and control measures is mandatory to alleviate the disease’s direct medical costs. Close monitoring of the chronic hepatitis stage is mandatory to prevent disease progression. Enhancement of vaccination efforts will lower the disease prevalence and its cost. The universal health insurance system which is gradually implemented in Egypt nowadays will be a cornerstone in relieving the economic stresses by allowing more access to high-quality health care services.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1186/s43066-021-00162-z</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1282-8521</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2090-6226 |
ispartof | Egyptian Liver Journal, 2021-12, Vol.11 (1), p.91-7, Article 91 |
issn | 2090-6226 2090-6218 2090-6226 |
language | eng |
recordid | cdi_proquest_journals_2812339394 |
source | DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals |
subjects | Age groups Broadway theater Chronic hepatitis B Control Development and progression Direct medical cost Disease Economic aspects Egypt Health care expenditures Health care industry Health care resources Hepatitis B Hepatology Hospitalization Infection Infections Laboratories Liver Liver cancer Liver cirrhosis Medical care Medical care, Cost of Medical research Medicine Medicine & Public Health Medicine, Experimental Morbidity Mortality National health insurance Original Research Article Patients Prevalence Questionnaires Transplantation of organs, tissues, etc Utilization |
title | Health care resources utilization and costs associated with different clinical stages of chronic hepatitis B in Egypt |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A14%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Health%20care%20resources%20utilization%20and%20costs%20associated%20with%20different%20clinical%20stages%20of%20chronic%20hepatitis%20B%20in%20Egypt&rft.jtitle=Egyptian%20Liver%20Journal&rft.au=Abd%20El-Halim,%20Jackleen%20Azer&rft.date=2021-12-20&rft.volume=11&rft.issue=1&rft.spage=91&rft.epage=7&rft.pages=91-7&rft.artnum=91&rft.issn=2090-6226&rft.eissn=2090-6226&rft_id=info:doi/10.1186/s43066-021-00162-z&rft_dat=%3Cgale_doaj_%3EA687542228%3C/gale_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2812339394&rft_id=info:pmid/&rft_galeid=A687542228&rft_doaj_id=oai_doaj_org_article_831825314b3f4fde94d19de769cbc551&rfr_iscdi=true |